◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › V › VTRS

Viatris Inc (VTRS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-09-19

Viatris Inc (VTRS) operates in the Pharmaceuticals industry and is headquartered in Canonsburg, United States with about 30,000 employees. Its market capitalization is roughly $19 billion. In the fiscal year ended 2025-12-31, VTRS reported $14.3B in revenue and ($3.5B) in net income.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

Interactive charts & full statements → Open the VTRS valuation workbench →

VTRS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$14.7B	$14.3B	$14.7B	$15.4B	$16.3B	$17.9B	$11.9B	$11.5B	$11.4B	$11.9B	$11.1B	$9.4B	$7.7B	$6.9B	$6.8B	$6.1B	$5.5B	$5.1B	$5.1B	$2.9B	$1.6B
Gross Profit	$5.1B	$5.0B	$5.6B	$6.4B	$6.5B	$5.6B	$3.8B	$3.9B	$4.0B	$4.8B	$4.7B	$4.2B	$3.5B	$3.0B	$2.9B	$2.6B	$2.2B	$2.1B	$2.1B	$1.2B	$844M
Gross Margin %	34.8%	35.1%	38.1%	41.7%	40.0%	31.2%	31.8%	33.9%	35.0%	40.2%	42.4%	44.7%	45.7%	44.0%	42.8%	41.8%	40.7%	40.7%	40.3%	40.1%	52.3%
Operating Income (EBIT)	—	($2.7B)	$10M	$766M	$1.6B	($34M)	($211M)	$716M	$906M	$1.4B	$699M	$1.5B	$1.4B	$1.1B	$1.1B	$1.0B	$722M	$523M	$298M	$372M	$428M
Operating Margin %	—	-18.6%	0.1%	5.0%	9.9%	-0.2%	-1.8%	6.2%	7.9%	12.1%	6.3%	15.5%	17.5%	16.4%	16.3%	16.4%	13.2%	10.3%	5.8%	12.8%	26.5%
Net Income	($411M)	($3.5B)	($634M)	$55M	$2.1B	($1.3B)	($670M)	$17M	$352M	$696M	$480M	$848M	$929M	$624M	$641M	$537M	$345M	$233M	($196M)	($1.5B)	$217M
Net Margin %	-2.8%	-24.6%	-4.3%	0.4%	12.8%	-7.1%	-5.6%	0.1%	3.1%	5.8%	4.3%	9.0%	12.0%	9.0%	9.4%	8.8%	6.3%	4.6%	-3.8%	-52.2%	13.5%
EBITDA	—	($395M)	$2.8B	$3.5B	$6.4B	$4.5B	$2.0B	$2.7B	$3.0B	$3.2B	$2.1B	$2.3B	$1.9B	$1.6B	$1.7B	$1.5B	$1.1B	$947M	$735M	($992M)	$683M
Earnings Per Share (EPS)	$-0.36	$-3.00	$-0.53	$0.05	$1.71	$-1.05	$-1.11	$0.03	$0.68	$1.30	$0.92	$1.70	$2.34	$1.58	$1.52	$1.22	$1.05	$0.76	$-0.64	$-5.90	$0.99
Shares Outstanding (M)	—	1,171M	1,193M	1,207M	1,217M	1,209M	601M	516M	516M	537M	520M	497M	398M	394M	420M	439M	329M	307M	304M	257M	219M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VTRS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$3.8B	$3.5B	$3.7B	$3.8B	$3.6B	$3.3B	$3.5B	$3.8B	$3.8B
Gross Profit	$1.5B	$1.2B	$1.1B	$1.4B	$1.3B	$1.2B	$1.2B	$1.5B	$1.4B
Gross Margin %	38.8%	32.9%	30.6%	36.8%	37.2%	35.7%	34.4%	38.9%	38.1%
Operating Income (EBIT)	—	($80M)	($266M)	$252M	$233M	($2.9B)	($180M)	$226M	($240M)
Operating Margin %	—	-2.3%	-7.2%	6.7%	6.5%	-88.6%	-5.1%	6.0%	-6.3%
Net Income	($119M)	$176M	($340M)	($128M)	($5M)	($3.0B)	($516M)	$95M	($326M)
Net Margin %	-3.2%	5.0%	-9.2%	-3.4%	-0.1%	-93.5%	-14.6%	2.5%	-8.6%
EBITDA	—	$644M	$543M	$800M	$578M	($2.3B)	$340M	$906M	$540M
Earnings Per Share (EPS)	$-0.10	$0.15	$-0.30	$-0.11	$-0.00	$-2.55	$-0.43	$0.08	$-0.27
Shares Outstanding (M)	—	1,175M	1,153M	1,165M	1,173M	1,192M	1,193M	1,200M	1,191M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VTRS Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$2.3B	$2.3B	$2.3B	$2.8B	$3.0B	$3.0B	$1.2B	$1.8B	$2.3B	$2.1B	$2.0B	$2.0B	$1.0B	$1.1B	$949M	$720M	$931M	$605M	$384M	$168M	$390M
Capital Expenditures (CapEx)	—	$379M	$326M	$474M	$443M	$509M	$681M	$406M	$252M	$276M	$390M	$363M	$325M	$335M	$305M	$280M	$193M	$154M	$165M	$111M	$162M
Free Cash Flow (FCF)	—	$1.9B	$2.0B	$2.3B	$2.5B	$2.5B	$551M	$1.4B	$2.1B	$1.8B	$1.7B	$1.6B	$690M	$772M	$644M	$441M	$739M	$451M	$219M	$57M	$228M
FCF Margin %	—	13.6%	13.4%	15.1%	15.4%	14.0%	4.6%	12.2%	18.3%	15.0%	15.0%	17.4%	8.9%	11.2%	9.5%	7.2%	13.6%	8.8%	4.3%	2.0%	14.2%
Dividends Paid	—	$561M	$575M	$576M	$582M	$399M	$8M	$0M	$399M	—	—	—	—	—	—	—	$139M	$139M	$137M	$30M	$51M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VTRS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$382M	$388M	$816M	$745M	$220M	$536M	$483M	$826M	$379M
Capital Expenditures (CapEx)	—	$40M	$265M	$100M	$54M	$76M	$153M	$85M	$59M
Free Cash Flow (FCF)	—	$348M	$550M	$645M	$166M	$459M	$329M	$741M	$320M
FCF Margin %	—	9.9%	14.9%	17.2%	4.6%	14.1%	9.3%	19.8%	8.4%
Dividends Paid	—	$140M	$138M	$140M	$140M	$143M	$143M	$143M	$146M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VTRS Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$35.0B	$37.2B	$41.5B	$47.7B	$50.0B	$54.8B	$61.6B	$31.3B	$32.7B	$35.8B	$34.7B	$22.3B	$15.8B	$15.3B	$11.9B	$11.6B	$11.5B	$10.8B	$10.4B	$11.4B	$4.3B
Cash & Cash Equivalents	$886M	$1.3B	$735M	$992M	$1.3B	$701M	$844M	$476M	$388M	$292M	$999M	$1.2B	$226M	$291M	$350M	$384M	$686M	$428M	$597M	$484M	$1.3B
Total Liabilities	$20.8B	$22.5B	$22.9B	$27.2B	$28.9B	$34.4B	$38.6B	$19.4B	$20.6B	$22.5B	$23.6B	$12.5B	$12.5B	$12.3B	$8.6B	$8.1B	$7.9B	$7.7B	$7.6B	$7.9B	$2.6B
Total Debt (Short + Long-Term)	$13.6B	$14.5B	$14.1B	$18.2B	$19.3B	$23.2B	$25.9B	$12.7B	$13.8B	$14.7B	$15.5B	$1.0B	$2.8B	$456M	$397M	$817M	$167M	$191M	$154M	$550M	$233M
Total Shareholders' Equity	$14.3B	$14.7B	$18.6B	$20.5B	$21.1B	$20.5B	$23.0B	$11.9B	$12.2B	$13.3B	$11.1B	$9.8B	$3.3B	$2.9B	$3.3B	$3.5B	$3.6B	$3.1B	$2.8B	$3.4B	$1.7B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VTRS viewer.

VTRS Metric Deep Dives

Other Companies in Pharmaceuticals

MRK · Merck & Co. — $362 billion
PFE · Pfizer — $158 billion
BMY · Bristol Myers Squibb — $129 billion
ZTS · Zoetis — $30 billion
LLY · Lilly (Eli) — $1.03 trillion
JNJ · Johnson & Johnson — $651 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← VTR All “V” companies VTS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.